TABLE 1.
Demographic, Perinatal and Neonatal Characteristics of the NEURO Follow-up Cohort (N = 445)
| Characteristics | |
|---|---|
| Birth weight, mean ± SD, g | 856 (190) |
| EGA, mean ± SD, wk | 25.9 (1.0) |
| Multiple gestation | 102 (22.9) |
| Race | |
| Non-Hispanic black | 141 (31.7) |
| Non-Hispanic white | 192 (43.2) |
| Hispanic | 98 (22.0) |
| Other | 14 (3.2) |
| Boy | 246 (55.3) |
| Any antenatal steroids | 428 (96.2) |
| Cesarean delivery | 306 (68.8) |
| PDA diagnosed | 222 (50) |
| Late sepsisa | 144 (32) |
| NEC diagnosed | 32 (7) |
| Severe ROPb | 48/412 (12) |
| Surgery for PDA or NEC or ROP | 84 (19) |
| Postnatal steroidsc | 38 (9) |
| BPDd | 159 (36) |
| Neonatal neuroimaging | |
| Early CUS adverse finding (grade III or IV ICH or cPVL) | 43 (9.7) |
| Late CUS adverse finding (moderate or severe VE, cPVL, porencephalic cyst, or shunt) | 26 (5.8) |
| Moderate or severe WMA on MRI | 86 (19.3) |
| Any cerebellar lesions on MRI | 72 (16.2) |
| Significant cerebellar lesions on MRI | 46 (10.3) |
Data presented as n (%) unless otherwise specified.
a
Late sepsis: culture-proven sepsis from 7 d of age to discharge and treated with antibiotics for at least 5 d.
b
Severe ROP: threshold ROP,13,16 ophthalmologic surgery, or the use of bevacizumab treatment of retinopathy.
c
Postnatal steroids: any corticosteroid given for prevention or treatment of BPD.
d
BPD: receipt of >30% supplemental oxygen at 36 wk or the need for positive-pressure support or, in the case of infants requiring >30% oxygen, the need for any supplemental oxygen at 36 wk after an attempt at withdrawal of oxygen.